p53 activation by blocking Snail: a novel pharmacological strategy for cancer

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• p53 is a critical tumor suppressor gene regulating apoptosis, cell cycle arrest, and senescence.
• Mutations or inactivation of p53 occur in over 50% of human cancers, hindering effective cancer therapy.
• p53 mutations can exhibit dominant-negative effects, further complicating therapeutic strategies.

Purpose of the Study:

• To elucidate a novel mechanism of p53 inactivation mediated by the oncogenic K-Ras-Snail axis.
• To develop and evaluate small chemical compounds (GN25, 29) for reactivating p53 suppressed by K-Ras-Snail.
• To explore the therapeutic potential of targeting the K-Ras-Snail-p53 axis in K-Ras mutated cancers.

Main Methods:

• Investigated the K-Ras-Snail signaling pathway's role in p53 inactivation.
• Synthesized and utilized small molecules (GN25, 29) as inhibitors of the Snail-p53 interaction.
• Assessed the efficacy of these inhibitors in reactivating p53 function in cancer models.

Main Results:

• Identified a novel mechanism where the K-Ras-Snail axis inactivates p53.
• Demonstrated that small chemicals GN25 and 29 can effectively reactivate suppressed p53.
• Showcased the potential for these inhibitors to counteract dominant-negative effects of mutant p53.

Conclusions:

• The K-Ras-Snail axis represents a significant mechanism for p53 inactivation in cancer.
• Small molecule inhibitors targeting Snail offer a promising therapeutic strategy for K-Ras mutated cancers, including pancreatic, colon, and lung cancers.
• This approach provides a new avenue for treating cancers driven by K-Ras mutations by restoring p53 tumor suppressor activity.